Progress, Potential, and Possibilities

Send us Fan MailWhat if we could recreate the inside of a star - not in theory, but inside a laboratory on Earth using the world's most powerful lasers?Dr. Mario Manuel, Ph.D. is a plasma physicist and laser-science researcher at whose work sits at the frontier of fusion energy, laboratory astrophysics, high-energy-density physics, and advanced laser diagnostics. Trained in applied plasma physics and aerospace engineering, Dr. Manuel has spent his career developing new ways to visualize and understand the extreme electromagnetic environments created when ultra-powerful lasers interact with matter.Dr. Manuel's research has spanned some of the most ambitious scientific efforts underway today - from inertial fusion energy and plasma-instability control to recreating supernova-like shock waves in the laboratory and generating ultra-intense gamma-ray and particle beams using petawatt-class lasers. Early in his career, Dr. Manuel helped pioneer advanced proton-radiography techniques capable of imaging invisible electric and magnetic fields inside laser-produced plasmas, work that opened new windows into the turbulent physics that can either enable or destroy fusion reactions.Today at General Atomics ( https://www.ga.com/ ), Dr. Manuel is involved in next-generation high-repetition-rate laser systems and the GALADRIEL ( https://www.ga.com/galadriel/ ) facility, where researchers are developing the automation, diagnostics, AI-driven optimization, and rapid experimental capabilities that may ultimately make practical laser fusion energy possible. His work also bridges into laboratory astrophysics, where miniature laser-driven plasmas are used to study the same collision-less shocks, turbulence, and magnetic-field generation processes that occur in supernova remnants and other extreme cosmic environments.With collaborations spanning facilities such as the National Ignition Facility in Livermore, California, and the OMEGA Laser Facility in Rochester, New York, along with partnerships across the fusion-energy and laboratory-astrophysics communities, Dr. Manuel represents a new generation of interdisciplinary scientists using ultra-powerful lasers not only to pursue practical fusion energy, but also to recreate and study some of the most extreme physical processes in the universe. From plasma turbulence and magnetic-field generation to collision-less shocks and high-energy particle acceleration, his work connects the quest for clean energy with the physics of stars, supernovae, and cosmic plasmas.#fusionenergy #nuclearfusion #nationalignitionfacility #laserscience #plasmaphysics #labastrophysics #supernova #gammaRays #particlephysics #inertialconfinementfusion #cleanenergy #futureofenergy #deeptech #sciencepodcast #generalatomics #livermore #omegaLaser #highenergyphysics #physics #aiinscience #fusionbreakthrough #scienceinterviewSupport the show

Send us Fan MailWhat if modern medicine has become incredibly good at saving children's lives…but society still hasn't figured out how to help many of those children truly live afterward?Dr. Nicholas Holekamp, MD is the Chief Health Transformation Officer at Ranken Jordan Pediatric Bridge Hospital in St. Louis ( https://rankenjordan.org/about-us/leadership/nicholas-holekamp-md/ ), one of only a handful of pediatric bridge hospitals in the United States and the only one of its kind in Missouri ( www.RankenJordanFoundation.org ).For more than two decades, Dr. Holekamp has helped pioneer a radically different approach to caring for children with complex medical conditions through Ranken Jordan's innovative “Care Beyond the Bedside” model - a philosophy built around a deceptively simple but powerful idea: children heal better when they are active, engaged, social, and out of bed.Under Dr. Holekamp's leadership, Ranken Jordan evolved from a small 26-bed pediatric nursing facility into a nationally recognized 60-bed specialty hospital focused on helping medically complex children transition safely from intensive hospital care back to home and community life.A graduate of Dartmouth College and Saint Louis University School of Medicine, Dr. Holekamp completed his pediatric residency at Cardinal Glennon Children's Medical Center before joining Ranken Jordan in 2000. Along the way, he has become one of the leading voices in pediatric complex care and transitional medicine.Dr. Holekamp's work has combined clinical care, hospital transformation, and research - including published studies demonstrating how movement, play, environment, and family-centered care can improve outcomes for medically fragile children while potentially reducing healthcare utilization and costs.Dr. Holekamp has been recognized for both his medical leadership and community impact, including receiving the Missouri Foundation for Health's Dr. Corinne Walentik Leadership in Health Award and delivering a TEDxStLouis talk on the future of pediatric healing and healthcare transformation.Today, as Chief Health Transformation Officer, Dr. Holekamp is focused on sharing the lessons of Ranken Jordan with hospitals and healthcare systems across the country - challenging long-held assumptions about what healing environments for children should actually look like.#Pediatrics #ChildrensHospital #MedicalEthics #HealthcareInnovation #PediatricCare #Neurodevelopment #ChildrenWithMedicalComplexity #HealthcarePodcast #Medicine #PediatricMedicine #HospitalInnovation #CriticalCare #Bioethics #FamilyCenteredCare #HealthcareLeadership #MedicalResearch #VentilatorCare #Rehabilitation #PediatricRehabilitation #FutureOfHealthcare #HealthcareSystems #MedicalTechnology #ProgressPotentialPossibilities #HealthcareTransformation #PediatricICUSupport the show

Send us Fan MailOver the last several years, artificial intelligence has transformed from a speculative concept in healthcare into one of the most heavily funded movements in pharmaceutical and biotech history.But in 2026, the conversation is changing. The question is no longer whether AI can generate molecules, analyze pathology slides, or identify patterns in clinical data. The real question is: which of these technologies can survive the complexity of biology, regulatory scrutiny, clinical validation, and real-world deployment?Today we're joined once again by returning guest Bill Taranto, President and Founding Partner of the Merck Global Health Innovation Fund ( https://www.merckghifund.com/ ), alongside Managing Director, Dr. David Rubin, who brings a deep scientific background spanning molecular biology, oncology, precision medicine, and digital health investing.Together, Bill and David sit at a unique intersection of pharma strategy, venture investing, translational science, and clinical deployment. Through investments across AI-driven drug discovery, precision medicine, diagnostics, and digital health - including early involvement with companies like PathAI - they've had a front-row seat to what's actually working in AI-enabled healthcare…and what still breaks down when these systems encounter real-world medicine.Today we'll explore where AI is genuinely creating value across the pharmaceutical stack, why some approaches are beginning to achieve meaningful validation, what investors and pharma companies are now demanding beyond hype, and how entirely new experimental models - from organoids to AI-native biology platforms - may reshape the future of drug development.#AI #ArtificialIntelligence #DrugDiscovery #Biotech #Pharma #HealthcareAI #PrecisionMedicine #DigitalHealth #Oncology #PathAI #Roche #Biology #MachineLearning #BiotechInvesting #VentureCapital #Merck #DigitalPathology #ClinicalTrials #FutureOfMedicine #LifeSciences #AIHealthcare #MedicalInnovation #Biotechnology #CancerResearch #PrecisionOncology #Bioinformatics #HealthcareInnovation #Pharmaceuticals #MedTech #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailFor decades, agriculture and energy were treated as separate worlds. But what happens when farms become part of the global energy infrastructure? Ofer Haviv joins us to discuss the rise of castor as a next-generation industrial crop, the future of sustainable aviation fuel, and how AI-driven biology is transforming agriculture itself.Ofer Haviv is CEO of Casterra ( https://casterra.co/ ) and longtime President and CEO of Evogene ( https://evogene.com/ ), one of the pioneers in computational biology and AI-driven agricultural innovation.For more than two decades, Ofer has helped lead the transformation of crop science from traditional breeding into a data-driven discipline powered by predictive biology, artificial intelligence, and advanced genomics. He played a key role in Evogene's spin-off from Compugen in 2002 and has guided the company through its evolution into a global computational biology platform with applications spanning agriculture, human health, industrial biotechnology, and sustainable materials.Today, Ofer also serves as CEO of Casterra, an Evogene subsidiary focused on transforming castor farming into a scalable industrial platform for the future bioeconomy. Through elite castor seed varieties and integrated farming solutions, Casterra is helping address growing global demand for sustainable feedstocks used in biofuels, aviation fuel, lubricants, polymers, cosmetics, and other bio-based industries.With increasing pressure on the world to decarbonize transportation, strengthen energy security, and develop more sustainable industrial supply chains, Casterra's work sits at the convergence of agriculture, climate technology, and renewable energy innovation.Ofer holds a degree in Economics and Accounting from Tel Aviv University and is a Certified Public Accountant in Israel.#OferHaviv #Casterra #Evogene #Biofuels #SustainableAviationFuel #SAF #ClimateTech #Agriculture #AgTech #Biotech #AI #ArtificialIntelligence #ComputationalBiology #RenewableEnergy #GreenEnergy #FutureOfEnergy #IndustrialBiotech #Castor #SustainableFarming #EnergyTransition #Bioeconomy #CarbonNeutral #FutureTech #ClimateInnovation #CleanTech #Aviation #JetFuel #SustainableTechnology #FoodTech #PrecisionAgricultureSupport the show

Send us Fan MailEvery once in a while, a simple question changes medicine forever.For decades, chronic and traumatic wounds were among the most frustrating problems in healthcare. Doctors could clean wounds, dress wounds, and hope for healing - but many patients remained trapped in cycles of infection, inflammation, and failed recovery.Then came one deceptively simple idea:  What happens if you apply vacuum?That question led to the creation of Vacuum Assisted Closure - better known worldwide as V.A.C.® Therapy ( https://www.solventum.com/en-us/home/medical/advanced-wound-care/negative-pressure-wound-therapy/vac-therapy/ ) - developed by plastic surgeon Dr. Louis Argenta and biomedical engineer Dr. Michael Morykwas ( https://www.renovoconcepts.com/michaelmorykwasbio ).The technology transformed wound care by using controlled negative pressure to remove fluid, stimulate blood flow, encourage tissue growth, and accelerate healing. What began as a bold experiment evolved into one of the most important advances in modern medicine, helping more than 20 million patients worldwide - from burn victims and diabetic patients to wounded soldiers returning from Iraq and Afghanistan.For this groundbreaking work, Drs. Argenta and Morykwas were inducted into the National Inventors Hall of Fame ( https://www.invent.org/inductees/michael-morykwas ).Today, we're joined by Dr. Michael Morykwas - bioengineer, inventor, scientist, and lifelong tinkerer - to explore the origins of this revolutionary technology, the science behind mechanobiology and wound healing, the long road from prototype to global adoption, and what the future of regenerative medicine may look like next.Photo Credit - National Inventors Hall of Fame #MichaelMorykwas #VACtherapy #WoundHealing #RegenerativeMedicine #Mechanobiology #BiomedicalEngineering #MedicalInnovation #NegativePressureWoundTherapy #TissueEngineering #HealthcareInnovation #PlasticSurgery #Bioengineering #MedicalBreakthrough #Inventor #NationalInventorsHallOfFame #RegenerativeScience #MilitaryMedicine #FutureOfMedicine #MedTech #SciencePodcast #InnovationPodcast #HealthcareTechnology #StemCells #WoundCare #MedicalScienceSupport the show

Send us Fan MailFor years, T cell therapies have transformed blood cancers - but solid tumors have remained one of the hardest problems in medicine. Now a new company called Deck Bio believes the issue isn't just finding a better target...it's that cancer may never have been a single-target disease in the first place.Dr. Jack Silberstein, Ph.D. is the Founder and CEO of Deck Bio ( https://deck.bio/ ), a biotechnology company developing next-generation T cell engager therapies designed to address one of the most persistent challenges in solid tumor immunotherapy: antigen heterogeneity and immune escape.Deck Bio's platform takes a multi-target approach, engineering T cell receptors to simultaneously recognize multiple peptide-MHC (pMHC) complexes, with the goal of improving both tumor specificity and durable anti-tumor activity while reducing the on-target/off-tumor toxicity that has limited earlier T cell engager strategies.Prior to founding Deck Bio, Dr. Silberstein trained as an immunology Ph.D. at Stanford University, where he was a Bio-X interdisciplinary fellow, and later worked at Johns Hopkins University on early clinical and translational oncology studies, including work on AR-V7 as a resistance biomarker in prostate cancer and early immune checkpoint combination trials. His background spans both deep immunology and real-world clinical translation in oncology.Dr. Silberstein joins us following Deck Bio's recent preclinical presentation at AACR 2026 in San Diego, where the company shared early data on its multi-pMHC targeting strategy.#DeckBio #JackSilberstein #Immunotherapy #CancerResearch #TCellEngagers #Biotech #AACR2026 #SolidTumors #CancerTherapy #TCellTherapy #PrecisionMedicine #Oncology #TCRTherapy #CancerInnovation #Biotechnology #ImmuneSystem #CellTherapy #CancerBreakthrough #SyntheticBiology #FutureOfMedicineSupport the show

Send us Fan MailWhat if the next pandemic could be identified, diagnosed, and targeted with programmable CRISPR therapeutics before it spreads globally? That's exactly what Seek Labs is trying to build.Jared Bauer is CEO of Seek Labs ( https://seeklabs.com/ ), a clinical-stage TechBio company developing an integrated platform that combines AI-driven genomic intelligence, rapid field diagnostics, and CRISPR-based therapeutics designed to identify and potentially counter emerging pathogens faster than ever before.In a world where outbreaks can spread globally before traditional systems even identify the threat - as we saw with COVID and more recently with delayed hantavirus confirmation cases - Seek Labs is asking a bold question: what if diagnostics and therapeutics could be programmed and deployed at the speed of software?Jared is also Chairman of BioHive Utah ( https://www.biohive.com/ ), one of the fastest-growing life science ecosystems in the United States, and has spent his career at the intersection of biotech innovation, AI, diagnostics, and public health preparedness.We discuss AI-driven drug discovery, CRISPR therapeutics, programmable outbreak response, biodefense infrastructure, and what the next generation of pandemic preparedness may actually look like.#SeekLabs #JaredBauer #CRISPR #AI #Biotech #PandemicPreparedness #BioDefense #Diagnostics #Therapeutics #GeneEditing #SyntheticBiology #InfectiousDisease #FutureOfMedicine #HealthcareInnovation #PrecisionMedicine #Biotechnology #BARDA #ARPAH #DiseaseSurveillance #TechBio #OutbreakResponse #Biosecurity #AIinHealthcare #MedicalInnovation #PodcastSupport the show

Send us Fan MailMost people assume national security delays are about technology.They're not.  They're about paperwork - and it can take up to two years just to deploy software the government already wants.Andrew Black is a national security entrepreneur, cybersecurity executive, and emerging technology strategist whose career has sat at the intersection of AI, defense, cyber risk, and global security operations.Andrew is currently the CEO of Kovr.ai ( https://kovr.ai/ ) an AI-native cyber compliance platform focused on one of the biggest bottlenecks in modern national security: getting software and cloud systems authorized for use in highly regulated and classified environments. Kovr.ai is using AI to automate complex compliance frameworks like FedRAMP and CMMC, helping organizations become “ATO-ready” (Authority to Operate) in minutes rather than months.  Andrew also now serves as Chief Strategy Officer of Fortreum  ( https://fortreum.com/ ) which recently acquired Kovr.aiBefore joining Kovr.ai, Andrew led emerging technology initiatives at Amazon Web Services (AWS), where he worked with government leaders on next-generation capabilities spanning artificial intelligence, generative AI, quantum computing, high-performance computing, edge systems, and space technologies.Andrew's career has also included leadership roles at Gartner, advisory work with the Krach Institute for Tech Diplomacy at Purdue, venture investing with NextGen Venture Partners, and teaching national security and data analysis as adjunct faculty at Georgetown University Walsh School of Foreign Service.Earlier in his career, Andrew worked in counter-terrorism, threat modeling, and risk analytics, building data-driven systems to allocate anti-terrorism resources and anticipate geopolitical instability in frontier and conflict-affected regions.A graduate of University of St Andrews and Georgetown University, Andrew has spent two decades helping government and industry navigate increasingly complex technological and security landscapes - and today he's focused on transforming how AI can accelerate trust, compliance, and operational readiness across the defense ecosystem.#AI #Cybersecurity #NationalSecurity #DefenseTech #FedRAMP #CMMC #ATO #ArtificialIntelligence #GovTech #CyberCompliance #CloudSecurity #KovrAI #DoD #ZeroTrust #EmergingTech #Startup #MachineLearning #CyberDefense #FutureOfAI #GovernmentTechnologySupport the show

Send us Fan MailEvery product you buy has a journey - but for most companies, that journey is basically invisible until something goes wrong.Today we are diving into one of the most overlooked - yet absolutely essential - pieces of global commerce: the pallet. Every year, billions of products move across the world sitting on these simple platforms, but despite the rise of AI, IoT, robotics, and digital supply chains, the pallet itself has remained largely unchanged for decades.Our guest today is trying to change that.Joining us is Rodrigo Castro, Co-Founder and President of Adaptive Pallet Solutions ( APS - https://adaptivepalletsolutions.com/ ), a Philadelphia-based company building what they call a “supply chain intelligence platform” powered through smart pallets. APS leases 100% recyclable plastic pallets embedded with IoT sensors capable of tracking location, temperature, humidity, shock, load status, theft, and other real-time logistics data across global supply chains.Rather than treating pallets as disposable infrastructure, APS is transforming them into connected data assets - helping Fortune 500 companies gain visibility into food, pharmaceutical, retail, and logistics operations while also reducing waste and improving sustainability.Rodrigo brings a fascinating mix of finance, infrastructure, and operational thinking to the problem. Prior to APS, he worked in investment banking at PNC Bank within the Financial Institutions Group, was an investor at LL Funds focused on specialty finance and fintech, and is also Co-Founder and Managing Partner at 912 Capital Partners, where he focuses on major secular growth themes including manufacturing, electrification, digital infrastructure, and supply chains.Rodrigo is also a graduate of Amherst College, where he studied Economics and German, and spent time studying abroad at the University of Vienna.Today we'll explore how something as humble as the pallet became a massive blind spot in modern logistics, why the future of supply chains may depend on real-time physical intelligence, and how connected infrastructure could reshape everything from pharmaceuticals and food safety to retail and global trade resilience.#SupplyChain #Logistics #Innovation #IoT #SmartPallets #ColdChain #PharmaLogistics #FoodSupplyChain #RetailTech #InsurTech #AIinLogistics #Sustainability #CircularEconomy #IndustrialIoT #DigitalTransformation #WarehouseAutomation #SupplyChainVisibility #FutureOfLogistics #TechInnovation #AdaptivePalletSolutionsSupport the show

Send us Fan MailWhat if medicines could actually “decide” when and where to activate inside the body? MIT-trained synthetic biologist Dr. Jacob Becraft, Ph.D. is building programmable therapies that behave less like traditional drugs…and more like biological software.Dr. Becraft is Co-Founder and CEO of Strand Therapeutics ( https://www.strandtx.com/ ), a company pioneering what may become one of the next great frontiers in medicine: programmable mRNA therapeutics.Long before mRNA became a household term through COVID vaccines, Dr. Becraft and his colleagues at MIT were developing what has been described as the world's first synthetic biology programming language for mRNA - technology designed not simply to deliver genetic instructions, but to create logic-driven therapies capable of making decisions inside living cells.Now Strand is translating that vision into cancer therapeutics, with early clinical data from its lead candidate STX-001 showing responses in patients with advanced solid tumors who had exhausted conventional options - including evidence of systemic immune activity and even complete responses.Beyond the science, Jake is also a leading voice in synthetic biology, biotech entrepreneurship, and the future relationship between software, biology, and medicine.#StrandTherapeutics #JacobBecraft #SyntheticBiology #mRNA #ProgrammableMedicine #CancerImmunotherapy #Immunotherapy #Biotech #PrecisionMedicine #GeneTherapy #SyntheticBiologyEngineering #FutureOfMedicine #Oncology #CAR_T #mRNATherapeutics #Bioengineering #IL12 #RNA #MIT #CellTherapy #Longevity #Biotechnology #MedicalInnovation #NextGenMedicine #CancerResearch #AIinBiology #HealthcareInnovation #GeneticMedicine #ScientificBreakthrough #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailBladder cancer treatment is entering a new era. From gene therapy and bladder preservation to AI-assisted diagnostics and the challenge of detecting “hidden” CIS, Dr. Ravi Chauhan, MD, FACS breaks down the technologies and clinical decisions reshaping urology in 2026.Dr. Ravi Chauhan, MD, FACS ( https://conradpearson.com/our-specialists/ravi-d-chauhan-m-d-facs/ ) is a board-certified urologist, fellowship-trained uro-oncology specialist, and one of the leading voices in advanced kidney and bladder cancer care in the Mid-South.Born and raised in Memphis, Tennessee, Dr. Chauhan graduated Cum Laude from Rhodes College with a degree in molecular biology before earning his M.D. and completing both his general surgery internship and urologic surgery residency at The University of Tennessee Health Science Center. He joined the Conrad Pearson Clinic in 2005 and has since become a recognized leader in the treatment of advanced bladder and kidney cancers, with numerous publications and presentations to his name.Dr. Chauhan's path into medicine was deeply personal. Inspired by watching his father practice medicine and witnessing the profound impact physicians can have on patients and families, he developed a philosophy centered on treating every patient with the same compassion, respect, and attention he would want for his own family.In addition to his expertise in surgical urology and uro-oncology, Dr. Chauhan has become increasingly focused on one of the biggest challenges in modern bladder cancer management: identifying and treating high-risk non–muscle invasive bladder cancer - or NMIBC, particularly  carcinoma in situ - or CIS , which can often be difficult to detect in routine clinical practice.Today, we'll discuss the evolving diagnostic landscape for CIS, why missed or under-recognized disease can significantly impact treatment decisions, and the growing importance of collaboration between urologists and pathologists. We'll also explore how community urologists are navigating these rapidly evolving standards of care, the future of precision bladder cancer management, and what it means for patients facing this disease.We'll also discuss bladder-sparing approaches, including Adstiladrin® (nadofaragene firadenovec-vncg), an intravesical gene therapy for adults with high-risk Bacillus Calmette-Guerin (BCG)-unresponsive NMIBC with CIS, with or without papillary ( https://www.adstiladrin.com/ ).ADSTILADRIN should not be used in patients with hypersensitivity to interferon alfa or its components, and individuals who are immunosuppressed or immune-deficient should not handle or receive the therapy. Delaying cystectomy in patients with BCG-unresponsive CIS could lead to development of muscle invasive or metastatic bladder cancer, which can be lethal. If patients with CIS do not have a complete response to treatment after 3 months or if CIS recurs, consider cystectomy.The most common adverse reactions include urinary discharge, fatigue, bladder spasm, urgency to urinate, and blood in urine. Patients should consult their healthcare provider regarding all medications and report any side effects. Please see full Prescribing Information  ( https://d2hu1op93domjx.cloudfront.net/wp-content/uploads/sites/12/2026/03/24101239/ADSTILADRIN-USPI-Mar.2026-CLEAN.pdf ) for additional details.#BladderCancer #Urology #CancerResearch #BladderCancerAwareness #NMIBC #CarcinomaInSitu #CIS #UroOncology #GeneTherapy #CancerTreatment #PrecisionMedicine #BCG #BladderPreservation #MedicalInnovation #Oncology #CancerCare #Immunotherapy #HealthcareInnovation #UrologistSupport the show

Send us Fan MailDrowning is the leading cause of death for children ages 1 to 4 in multiple countries - yet it receives only a fraction of the attention of other public health crises. Why?Acacia Landfield is Associate Director, Principal Investigator, and Director of Policy & Implementation Science at The Drowning Research & Injury Prevention Policy Institute ( DRIPPI - https://www.drippi.org/ ), a multidisciplinary nonprofit consortium focused on reducing drowning deaths through research, education, systems thinking, and policy innovation.Acacia brings together an unusually broad background spanning public health, international diplomacy, education, implementation science, and aquatic safety. A lifelong swim coach and water safety educator, she has spent more than 25 years working across injury prevention, public policy, and community education, with a mission to address one of the world's most overlooked public health crises: childhood drowning.Acacia's work focuses on what she calls “universal basic aquatic competency” - the idea that early, gentle, developmentally informed water exposure can fundamentally change drowning outcomes across entire populations. Her research explores everything from breathing mechanics and motor learning in the water to the unintended downstream effects of flotation devices and inequities in aquatic infrastructure.Acacia is also helping reframe drowning prevention as part of a much larger conversation around climate resilience, disaster preparedness, urban planning, and health equity. As a 2024 Presidential Road Safety Scholar with the American Public Health Association, and an active contributor to climate and disaster preparedness initiatives, she is pushing for drowning prevention to be treated not as a niche issue, but as a core pillar of public health policy worldwide.Before co-founding DRIPPI and launching her research initiative SASE, Acacia held leadership and strategy roles at Massachusetts Institute of Technology, Harvard University, and the U.S. Department of State, where she worked on international education, diplomacy, and policy initiatives across multiple countries and sectors.Acacia holds degrees from Yale University and San José State University, is completing her MPH, and plans to pursue a DrPH focused on implementation science and injury prevention.Today, we'll explore why drowning remains one of the leading causes of death for children worldwide, why many current prevention models may be incomplete, and how a systems-level rethink of aquatic literacy could potentially save tens of thousands of lives each year.#DrowningPrevention #WaterSafety #AquaticLiteracy #Swimming #PublicHealth #ClimateResilience #ChildSafety #AquaticCompetency #DRIPPI #AcaciaLandfield #InjuryPrevention #SwimSafety #Aquatics #GlobalHealth #ClimateChange #ImplementationScience #AquaticEducation #SwimmingLessons #Parenting #HealthPodcast #Longevity #BrainHealth #DisasterPreparedness #HealthInnovation #WaterCompetencySupport the show

Send us Fan MailWhat if the biggest problem in nuclear energy isn't reactor technology…but paperwork, regulation, and institutional bottlenecks? Today we explore how AI could compress nuclear deployment timelines from decades to years.Kevin Kong is founder and CEO of Everstar ( https://everstar.ai/ ), a company building advanced AI reasoning systems designed to accelerate the deployment of nuclear power and modernize the infrastructure workflows surrounding the industry.Now when most people think about nuclear innovation, they think about reactors, fusion, uranium, or next-generation fuels. But Kevin and his team are focused on a very different problem - the massive institutional and cognitive bottlenecks that slow nuclear projects down. We're talking about years of regulatory review, millions of pages of compliance documentation, fragmented engineering systems, workforce shortages, operational complexity, and the enormous burden of coordinating safety-critical infrastructure at scale.Everstar is building AI systems intended to transform that process - converting dormant technical documentation into what they call ‘active intelligence.' Their platform combines advanced reasoning models, retrieval systems, multimodal AI, computer vision, and eventually robotics and sensor integrations to help accelerate engineering review, licensing, inspections, compliance workflows, and industrial decision-making inside the nuclear ecosystem.The company recently participated alongside the Department of Energy, Idaho National Laboratory, Argonne National Laboratory, and Microsoft in the DOE's Genesis Mission initiative - where Everstar demonstrated AI-assisted nuclear licensing workflows capable of generating NRC-style regulatory documentation in a fraction of the traditional timeline. The project has become an early example of how reasoning-based AI systems may begin operating inside some of the world's most highly regulated industries.Kevin's own background is unusually interdisciplinary. Before entering nuclear, he worked across software engineering, AI infrastructure, data systems, mobility technology, venture investing, and crisis logistics. He held leadership roles at companies including Bird and Rakuten, co-founded the AI data platform Hyperquery, studied economics and organizational sociology at Harvard University, and later pursued nuclear engineering coursework at Massachusetts Institute of Technology.In this conversation, we explore:- why nuclear energy may be essential for the future of AI and civilization-scale energy demand;- how reasoning systems could accelerate infrastructure deployment;- whether AI is ready for high-consequence industries like nuclear;- the future of AI-assisted licensing and compliance;- digital twins, robotics, and autonomous inspections;- the growing energy demands of AI datacenters;and - the deeper question of whether the true bottleneck to civilization is no longer physics…but institutional throughput itself.#NuclearEnergy #ArtificialIntelligence #AI #NuclearPower #EnergyAbundance #SMR #SmallModularReactors #NuclearInnovation #FutureOfEnergy #EnergyInfrastructure #AIInfrastructure #KevinKong #Everstar #AdvancedAI #NuclearEngineering #CleanEnergy #EnergySecurity #MachineLearning #IndustrialAI #Datacenters #FusionEnergy #TechPodcast #FutureTech #EnergyTech #Infrastructure #Robotics #ComputerVision #AIRevolution #NRC #EnergyTransitionSupport the show

Send us Fan MailFor decades, the beauty industry focused on creams, serums, and surface-level solutions. But what if aging skin is really a reflection of something much deeper happening inside our cells? Today's guest is François Vix, a longtime global beauty and wellness executive who has spent more than four decades at the intersection of skincare science, redox biology and oxidative stress research, and healthy aging.François began his career inside some of the world's biggest beauty and consumer health companies, holding senior leadership roles at L'Oréal, Lancôme, Biotherm, Johnson & Johnson, Neutrogena, and RoC Skincare, where he helped scale global brands across North America, Europe, Asia, and Latin America. Along the way, he became increasingly fascinated by a deeper scientific question: are we truly addressing the biological root causes of skin aging and inflammation - or simply treating the visible symptoms?That question eventually led François towards a new look at the science of redox biology, oxidative stress and the body's endogenous antioxidant systems, particularly the enzyme Superoxide Dismutase, or SOD - one of the body's first-line defenses against free radical damage.In 2001, François founded ISOCELL Laboratories ( https://www.glisodin.org/ ), focused on developing clinically studied approaches, including the GliSODin nutricosmetics brand, to supporting the body's own antioxidant defense mechanisms. Over the last two decades, the company has expanded internationally into more than 50 countries and has explored applications spanning skin health, inflammation, immune function, pigmentation disorders, and longevity science.Today, François speaks widely about redox biology and oxidative stress, integrative dermatology, and what he calls “beautyspan” - the idea that the future of beauty may increasingly be tied to cellular resilience, metabolic health, and healthy aging from within.#FrançoisVix #GliSODin #OxidativeStress #FreeRadicals #Longevity #Beautyspan #AntiAging #Perimenopause #MenopauseHealth #SkinHealth #HealthyAging #Mitochondria #RedoxBiology #Antioxidants #SOD #SuperoxideDismutase #IntegrativeMedicine #FunctionalMedicine #SkinLongevity #Biohacking #Healthspan #Inflammaging #LongevityScience #BeautyScience #Hormones #WomensHealth #CellularHealth #AgingResearch #WellnessPodcast #IraPastorSupport the show

Send us Fan MailSome of the most important cancer and autoimmune disease drugs in the world still require patients to sit in infusion chairs for hours - but that model may be about to change entirely.Matthew Huddleston is Chief Commercial Officer at Enable Injections ( https://enableinjections.com/ ), a medical device company focused on rethinking how large-volume biologic drugs are delivered to patients.Enable's core technology, the enFuse® on-body delivery system, is designed to shift certain therapies from traditional intravenous infusion to subcutaneous, wearable administration - potentially transforming treatment from something that requires a clinic visit into something that can be done at home, more comfortably and more conveniently.What makes this particularly interesting is where Enable sits in the broader biopharma ecosystem. The company is actively partnering with major pharmaceutical innovators including Sanofi, Roche, Incyte, and Viridian Therapeutics to support the transition of complex biologics into subcutaneous delivery formats.One of the clearest signals of momentum is that Sanofi's Sarclisa combined with Enable's on-body injector has been recommended for approval in Europe by the CHMP, with FDA review ongoing - highlighting that this is no longer theoretical innovation, but an emerging commercial pathway.Enable is also extending its platform through collaboration with Aptar Pharma and its digital health division, integrating companion software to support patients throughout therapy - bringing drug delivery closer to a connected care ecosystem, where device, data, and treatment adherence increasingly converge.On this episode we will unpack how this platform works, what it enables for pharma partners, and how wearable drug delivery could reshape the future of biologics.#biotech #medtech #drugdelivery #biologics #pharma #oncology #multiplemyeloma #medicaldevices #healthtech #wearabletech #subcutaneous #infusiontherapy #drugdevelopment #pharmaceuticalindustry #innovation #digitalhealth #enableinjections #sanofi #roche #incyte #clinicaltrialsSupport the show

Send us Fan MailMost autoimmune drugs suppress the immune system broadly - but what if you could selectively remove the antibodies actually causing disease? That's exactly what VYVGART is doing, and it may fundamentally change how we treat conditions like myasthenia gravis and CIDP.Dr. Luc Truyen, M.D., Ph.D., is Chief Medical Officer at argenx ( https://argenx.com/ ), where he leads the company's global clinical development and medical strategy across a rapidly advancing portfolio of immunology and neuromuscular therapies.A neurologist by training, Dr. Truyen brings more than two decades of experience in drug development, with a particular focus on neuroscience, neuroimmunology, and complex CNS disorders. Before joining argenx in 2021, he spent over 20 years at Johnson & Johnson and its pharmaceutical division Janssen Pharmaceuticals, where he held multiple senior leadership roles.Most notably, Dr. Truyen served as Global Head of Development for Neuroscience at Janssen, overseeing early- and late-stage pipelines spanning mood disorders, schizophrenia, and neurodegenerative and neuroinflammatory diseases. He also led global external affairs efforts in Alzheimer's disease, playing key roles in major international collaborations such as the Innovative Medicines Initiative and global dementia platforms.Earlier in his career, Dr. Truyen was Head of R&D and Chief Medical Officer of Janssen Alzheimer Immunotherapy, where he helped guide strategy across research, clinical development, and regulatory functions for novel immunotherapies targeting Alzheimer's disease.At argenx, Dr. Truyen is now helping drive the expansion of VYVGART (efgartigimod), a first-in-class FcRn antagonist, across multiple indications including myasthenia gravis and chronic inflammatory demyelinating polyneuropathy (CIDP), while advancing a broader pipeline aimed at transforming treatment paradigms in autoimmune and neuromuscular diseases.Dr. Truyen earned both his M.D. and Ph.D. in Neurology from the University of Antwerp.#LucTruyen #argenx #VYVGART #efgartigimod #MyastheniaGravis #CIDP #AutoimmuneDisease #Neurology #Biotech #Pharma #DrugDevelopment #FcRn #Immunology #RareDisease #ClinicalTrials #AAN2026 #MedicalInnovation #HealthcareInnovation #BiotechPodcast #LifeSciences #Neuroimmunology #IVIG #PrecisionMedicine #FutureOfMedicineSupport the show

Send us Fan MailIn the time it will take you watch this episode, over 2,000 people around the world will die from diseases driven by arterial plaque. But what if we could actually remove the toxic cholesterol already trapped inside arteries?Today we're diving into one of the biggest unsolved problems in medicine and aging: how do you actually remove arterial plaque instead of merely slowing its progression?Cardiovascular disease remains the world's leading killer, despite decades of statins, anti-inflammatory drugs, and newer RNA-based therapies. Most existing treatments help manage cholesterol and reduce risk, but very few directly target the toxic debris already embedded inside plaques.But what if we could literally extract some of the most dangerous oxidized cholesterol molecules from the body?My guest today is Dr. Matthew ‘Oki' O'Connor, Ph.D. - CEO and Co-Founder of Cyclarity Therapeutics ( https://cyclaritytx.com/ ), a biotech company developing engineered cyclodextrin molecules designed to bind and remove 7-ketocholesterol, or 7KC - a toxic oxidized cholesterol strongly implicated in atherosclerosis, inflammation, plaque instability, and even broader age-related diseases.Just recently, the company presented first-in-human clinical data at the American Heart Association Vascular Discovery Scientific Sessions showing dose-dependent urinary excretion of 7KC - potentially the first clinical evidence that this toxic molecule can be safely mobilized and removed from the human body.We'll discuss what 7KC actually is, why oxidized cholesterol may be a root driver of cardiovascular disease, how engineered cyclodextrins work like molecular “sponges,” what the new human data really shows - and what it would mean if medicine could move from slowing plaque progression to truly reversing it.#HeartDisease #Atherosclerosis #Longevity #CardiovascularDisease #PlaqueReversal #AgingResearch #Biotech #Cholesterol #OxidizedCholesterol #7Ketocholesterol #Cyclarity #Healthspan #PrecisionMedicine #AIinBiotech #DrugDiscovery #PreventiveMedicine #Cardiology #AntiAging #Lifespan #MedicalInnovation #SENS #FoamCells #Plaque #HeartAttack #StrokePreventionSupport the show

Send us Fan MailOne of the biggest drivers of hospital admissions isn't what most people think - it's fluid. Not infection, not surgery…fluid overload. And when the body stops responding to diuretics, medicine runs into a wall.Today we're exploring one of the most challenging and underappreciated frontiers in hospital medicine: fluid overload and the cardiorenal continuum - where heart failure and kidney dysfunction intersect in ways that dramatically affect outcomes, costs, and quality of life.Our guest is Ryan Marthaler, Vice President of Product Marketing and Business Development at Nuwellis, Inc. ( https://nuwellis.com/ ), a medical technology company focused on integrated fluid management solutions for both adult and pediatric patients.Ryan brings a two-decade career spanning Medtronic, St. Jude Medical, and digital health innovation - working at the intersection of clinical evidence, commercial strategy, and product development. At Nuwellis, he has helped drive a strategic shift toward earlier intervention in fluid management and stronger evidence-based commercialization.We'll be discussing the company's core therapy platform, including the Aquadex SmartFlow System, a controlled ultrafiltration system designed to remove excess fluid in patients with fluid overload who are unresponsive to diuretics.Beyond the technology, this conversation is really about a bigger question:How do we better manage fluid balance across the heart-kidney axis - and what happens when we intervene earlier, more precisely, and more consistently?#HeartFailure #CardiorenalSyndrome #FluidOverload #HealthcareInnovation #MedicalDevices #CriticalCare #Nephrology #Cardiology #HospitalMedicine #MedTech #Ultrafiltration #KidneyDisease #ICU #HealthTech #HealthcareEconomics #MedicalInnovationSupport the show

Send us Fan MailPharma has only explored a tiny fraction - less than one-tenth of one percent - of all possible drug-like molecules. So the question is: what happens when AI suddenly opens up the other 99.9%?Dr. Olga Nissan, Ph.D. is Vice President of Business Development at Evogene ( https://evogene.com/ ) where she leads pharmaceutical partnerships for the company's ChemPass AI generative chemistry platform - an advanced system designed to dramatically expand the searchable universe of drug-like molecules.With over 15 years of experience spanning biotech, pharma, and computational biology, Dr. Nissan operates at the intersection of science, strategy, and commercialization. Prior to Evogene, she was Co-Founder and CEO of Protica Bio, a precision oncology company focused on translating novel biological insights into therapeutic opportunities. Earlier in her career, she held scientific and operational roles at Teva Pharmaceutical Industries, as well as EcoPhage and BiomX, building expertise across microbiology, molecular biology, and translational R&D.Dr. Nissan has a strong track record of advancing technologies from early discovery through clinical and commercial partnerships, and of aligning cutting-edge innovation with the practical needs of pharmaceutical companies. She earned her Ph.D. and completed her postdoctoral training at the Weizmann Institute of Science.#DrugDiscovery #AIinPharma #GenerativeAI #Biotech #PharmaInnovation #ChemistryAI #MachineLearning #DrugDevelopment #PharmaceuticalIndustry #Bioinformatics #AIResearch #ChemPass #Evogene #ComputationalChemistry #FutureOfMedicine #DrugDesign #DeepLearning #HealthcareInnovation #BiotechNews #SciencePodcastSupport the show

Send us Fan MailWe used to think of DNA as something we read. Now we're starting to treat it like something we write - and that changes everything about how medicine gets made.Dr. Patrick Finn, Ph.D. is President and COO of Twist Bioscience ( https://www.twistbioscience.com/ ), a company that's helping turn biology into something you can engineer, iterate, and even industrialize. Dr. Finn has spent his entire career building the infrastructure layer of modern biotech - from sequencing and sample prep at Beckman Coulter and Invitrogen, to scaling commercial platforms at Agilent Technologies and now Twist.Dr. Finn also served as Vice President of Sales and Marketing for Enzymatics (recently acquired by QIAGEN), leading commercial activities for North America and Europe, delivering significant top line growth and expanding the base of business to business customers.So this isn't just a conversation about the future - it's about how the tools that make the future possible are actually built and deployed.On this episode we go beyond the buzzwords and dig into what it really means to “program biology”, and how close we actually are to designing medicines the way we design software.In addition to his role at Twist, Dr. Finn currently serves on the Scientific Advisory Board of Lasergen and previously served on the Scientific Advisory Board of Enzymatics. He holds a PhD in Nucleic Acid Chemistry from Southampton University and a BSc Hons in Chemistry from Heriot-Watt University.#SyntheticBiology #Biotech #DrugDiscovery #AIinHealthcare #ArtificialIntelligence #DNA #Genomics #Bioengineering #ProgrammableBiology #CRISPR #GeneTherapy #Biotechnology #LifeSciences #MachineLearning #AIResearch #PharmaInnovation #Biology #SciencePodcast #FutureOfMedicine #Biodesign #SyntheticDNA #GenomeSequencing #Bioeconomy #DeepTech #HealthTechSupport the show

Send us Fan MailWhat if saving a life isn't a single moment…but the beginning of thousands of future moments that only exist because someone chose to act?Today's guests are father-daughter duo Brad Newbury ( https://bradnewbury.com/ ) and Kiera Newbury ( https://kieranewbury.com/ ) - two voices at the intersection of emergency medicine, leadership, resilience, and human impact.Brad is a veteran Fire Captain and paramedic with nearly four decades on the front lines of emergency response. Over the course of his career, Brad has trained thousands of EMTs and paramedics around the world and built one of the pioneering online EMS education platforms through National Medical Education & Training Center Inc. ( NMETC -  https://nmetc.com/ ). Drawing from years of responding to crises, leading under pressure, and building businesses while serving in the firehouse, Brad recently authored the Amazon #1 bestseller The First Responder Advantage ( https://www.amazon.com/First-Responder-Advantage-Thriving-Business/dp/1967424837 ), a guide showing how the mindset and skills developed in emergency services can translate into entrepreneurship, leadership, and long-term impact.Joining Brad is his daughter Kiera, an EMT and emerging voice in emergency preparedness and public health advocacy. Together, Brad and Kiera co-authored The Saved Effect ( https://www.amazon.com/Saved-Effect-Stories-Reclaimed-Willing/dp/1637635923 ), a deeply human exploration of what happens after a life is saved - the ripple effects that extend into families, futures, communities, and generations. Through true stories of cardiac arrests, rescues, bystander CPR, and ordinary people stepping forward in extraordinary moments, the book asks a powerful question: What if the most important part of saving a life is everything that comes afterward?Together, Brad and Kiera bring a rare blend of frontline experience, leadership under pressure, entrepreneurship, public service, and deeply personal storytelling - all centered around one core belief: preparedness, courage, and the willingness to act can change the trajectory of countless lives.#FirstResponders #Paramedic #EMT #EmergencyMedicine #CPR #TheSavedEffect #BradNewbury #KieraNewbury #Firefighter #EMS #Healthcare #Preparedness #CardiacArrest #Leadership #Resilience #PublicHealth #MedicalStories #BystanderCPR #EmergencyResponse #LifeSaving #Podcast #HealthcareInnovation #MentalHealth #Trauma #EMSLeadershipSupport the show

Send us Fan MailFor decades, medicine focused on helping us live longer. Then came healthspan - helping us stay healthier longer. But what if the next frontier is something even deeper: joyspan… the quality, meaning, and fulfillment of the years we actually live?Today's conversation sits at the intersection of healthcare delivery, aging science, and one of the most important - and perhaps least discussed - questions in modern medicine:How do we help people not simply live longer… but live fulfilled lives?For decades, healthcare systems have largely measured success through clinical outcomes - lowering blood pressure, reducing hospitalizations, extending survival curves. But as populations age and chronic disease becomes increasingly intertwined with loneliness, purpose, financial security, cognition, and emotional well-being, a much broader picture of health is emerging.And that broader picture is exactly what we explore on this episode.Joining us is Dr. Sanjay Shetty, MD, President of CenterWell ( https://www.centerwell.com/ ) and a senior leader at Humana ( https://www.humana.com/ ). Dr. Shetty has one of the most fascinating and diverse backgrounds in modern healthcare - physician, radiologist, Harvard Medical School faculty member, Bain healthcare strategist, hospital system operator, value-based care leader, and now the executive overseeing one of America's largest senior-focused healthcare platforms spanning primary care, home health, pharmacy, and military health services.Under Dr. Shetty's leadership, CenterWell has increasingly focused on the idea that healthcare for older adults must move beyond episodic medicine and toward deeply integrated, personalized, and human-centered care.We're also joined by Dr. Kerry Burnight, Ph.D. ( https://drkerryburnight.com/ ) - gerontologist, educator, elder justice advocate, and author of the bestselling book Joyspan ( https://www.amazon.com/Joyspan-Science-Thriving-Lifes-Second/dp/1546007350 ). Dr. Burnight has spent decades studying aging not as decline, but as a stage of life that can be rich with purpose, connection, growth, and meaning. Her work challenges the fear-driven “anti-aging” narrative and introduces the concept of “joyspan” - the quality, vitality, and emotional richness of the years we live.Together, our guests bring two critically important perspectives:one from the operational front lines of transforming healthcare delivery for millions of seniors…and the other from the psychological, emotional, and social science of what actually makes later life meaningful.Part of today's discussion will center around a fascinating new CenterWell/Humana report titled Understanding Fulfillment for Older Adults: Definition and Impact ( https://assets.humana.com/is/content/humana/CenterWell%20Understanding%20Fulfillment%20in%20Older%20Adultspdf ), which examined more than 5,500 Americans over age 62 and attempted to quantify something medicine rarely measures directly: fulfillment.The findings are remarkable: that fulfillment in later life is influenced less by traditional clinical variables alone and more by factors like self-contentment, purpose, optimism, gratitude, emotional connection, and feeling appreciated by others.So on this episode, we ask:- Can healthcare systems measure fulfillment?- Should fulfillment become a clinical endpoint?- What happens when longevity medicine evolves from merely extending lifespan… to supporting joyspan?- And how do we redesign healthcare, communities, technologies, and even culture itself around what older adults actually value most?#Aging #Longevity #Healthspan #Joyspan #Fulfillment #CenterWell #Humana #SanjayShetty #KerryBurnight #HealthyAging #SeniorCare #FutureOfHealthcare #Gerontology #Loneliness #ValueBasedCare #HealthcareInnovation #PrecisionHealth #AgingWell #HealthcareTransformation #OlderAdults #LongevityScience #Purpose #Wellbeing #HomeHealthcare #PPPShowSupport the show

Send us Fan MailWhat if the future of medicine isn't about treating disease…but detecting it 20 years before symptoms ever appear? Dr. Julie Chen, MD is helping lead one of the newest precision-health companies trying to build that future.Dr. Julie Chen, MD is a physician operating at one of the most interesting intersections in modern medicine: rigorous clinical research, precision longevity medicine, integrative care, and the rapidly evolving world of AI-driven health optimization.Dr. Chen graduated Summa Cum Laude and Phi Beta Kappa from the University of Rochester before earning her M.D. with Distinction in Research and Alpha Omega Alpha honors from the university's School of Medicine. She went on to complete her internal medicine residency and later trained in integrative medicine under Andrew Weil at the University of Arizona Center for Integrative Medicine.Over the course of her career, Dr. Chen has conducted research and published work through institutions including the U.S. Food and Drug Administration, National Institutes of Health, National Cancer Institute, Mount Sinai School of Medicine, and University of Southern California.Dr. Chen has also become a prominent operational leader in the longevity industry, serving in executive medical roles at companies including Human Longevity, Inc., Vitagene, and now as Chief Medical Officer of Radence ( https://radence.com/ ) and Sidestep Health AI. She additionally serves as a Leadership Circle Advisor for the Buck Institute for Research on Aging.What makes Dr. Chen particularly compelling is that she has seen the longevity ecosystem from nearly every angle: academic medicine, FDA-level research, integrative clinical care, Silicon Valley health-tech, and AI-enabled prevention.In today's conversation, we'll explore where the science around longevity is genuinely promising, where the hype may be outrunning the evidence, how precision medicine is shifting toward early disease interception, and what responsible longevity medicine should actually look like in an era increasingly driven by consumer demand and social-media-driven health trends.#Longevity #Peptides #PrecisionMedicine #Healthspan #DrJulieChen #PreventiveMedicine #Biohacking #Aging #DiseaseInterception #GLP1 #LongevityMedicine #AIHealthcare #IntegrativeMedicine #HealthOptimization #HumanLongevity #FutureOfMedicine #MetabolicHealth #PreventiveHealth #Biotech #CraigVenter #Wearables #Biomarkers #Genomics #RadenceSupport the show

Send us Fan MailFor more than 30 years, small cell lung cancer has remained one of the most aggressive and difficult-to-treat cancers - marked by rapid progression, high relapse rates, and very few meaningful advances. But that may finally be starting to change.Today, we're joined by Dr. Angela Coxon, Ph.D., Vice President of Research and Development at Amgen ( https://www.amgen.com/ ), where she helps lead the development of next-generation therapies aimed at tackling exactly these kinds of challenges. Her work spans discovery research, translational medicine, and molecular oncology - bridging the gap between early scientific insight and real-world impact for patients.If you've been following the show, you may remember our conversation with Amgen's Dr. Ryan Potts, where we explored the emerging concept of Induced Proximity - the idea that instead of simply blocking biology, we can design drugs that bring components together to create entirely new functions. That idea is now playing out in the clinic through approaches like bispecific T-cell engagers, which physically link immune cells to cancer cells and force a targeted immune response - offering a new way to go after tumors that have historically been very hard to treat.Dr. Coxon earned her D. Phil in Molecular Biology from the University of Oxford and completed postdoctoral training in vascular biology at Harvard Medical School and Brigham and Women's Hospital. She has built her career at the intersection of cutting-edge biology and strategic drug development, contributing to Amgen's pipeline in areas of significant unmet need, including lung cancer.#SmallCellLungCancer #SCLC #CancerBreakthrough #Immunotherapy #CancerResearch #Biotech #Amgen #DrugDevelopment #Oncology #CancerTreatment #BiTE #BispecificAntibodies #InducedProximity #PrecisionMedicine #ClinicalTrials #MedicalInnovation #FutureOfMedicine #LungCancerAwareness #TranslationalMedicine #Biology #SciencePodcast #HealthcareInnovation #CancerTherapy #Pharma #NextGenMedicineSupport the show

Send us Fan MailPsychedelic medicine is no longer fringe science - it's now part of White House policy discussions, FDA fast-track programs, and a rapidly emerging neuropsychiatric industry. But can these therapies truly become scalable standards of care?Eric So is Co-Founder and Executive Chairman of Helus Pharma ( https://www.helus.com/ ), a company focused on developing next-generation serotonergic therapies for mental illness and advancing the broader field of psychedelic-assisted psychiatry. With a multidisciplinary background spanning science, law, finance, and entrepreneurship, Eric has spent his career building and scaling public and private companies across emerging sectors.Before launching Helus Pharma in 2019, Eric was involved with a number of high-growth ventures, including leadership roles at Globalive Technology and Therapix Biosciences Ltd., where he gained firsthand experience navigating the intersection of biotechnology innovation, regulation, and capital markets. He earned a Bachelor of Science in Cell Biology and Anatomy from McGill University before obtaining his law degree from University of Windsor.Today, Eric is helping shape conversations around how psychedelic medicines move from promising experimental therapies into scalable, evidence-based standards of care. His work comes at a pivotal moment for the field, as regulators, policymakers, clinicians, and industry leaders debate how to responsibly accelerate treatments for conditions such as depression, PTSD, addiction, and treatment-resistant mental illness - particularly for veterans and underserved patient populations. Following recent recognition of Helus Pharma in a White House discussion around psychedelic drug development and policy, Eric joins us to discuss the future of psychedelic medicine, the evolving regulatory landscape, and what it will take to translate scientific promise into real-world psychiatric care.#Psychedelics #MentalHealth #PsychedelicMedicine #Psychiatry #Neuroscience #Biotech #HelusPharma #EricSo #DepressionTreatment #PTSD #VeteransMentalHealth #PsychedelicTherapy #Neuroplasticity #PrecisionPsychiatry #FDA #DrugDevelopment #Ibogaine #Psilocybin #SerotonergicAgonists #FutureOfMedicine #Longevity #BrainHealth #Biotechnology #MentalHealthInnovation #HealthcareInnovationSupport the show

Send us Fan MailWhat if the next breakthrough cancer therapy can't be manufactured on Earth at all?In this episode, BioOrbit CEO Dr. Katie King explains how microgravity may unlock entirely new classes of medicines - from ultra-precise biologics to cancer therapies manufactured in orbit aboard future pharmaceutical factories in space.Dr. Katie King, Ph.D is a scientist, entrepreneur, and space-tech innovator working at the intersection of biotechnology, nanomedicine, and orbital manufacturing.Dr. King is the Co-Founder and CEO of BioOrbit ( https://www.bioorbit.space/ ), a pioneering company developing pharmaceutical manufacturing platforms in microgravity with the goal of revolutionizing cancer treatment. BioOrbit is focused on producing next-generation medicines in space - particularly highly structured biologics and crystallized therapeutics that may be difficult or impossible to manufacture optimally on Earth due to gravity-driven limitations. The company is preparing for a major in-orbit demonstration mission connected to the International Space Station and upcoming launch activity in 2026.Dr. King earned her Ph.D. in Nanomedicine and Chemistry from the University of Cambridge, where her research focused on self-assembling nanoparticle systems for biosensing and precision medicine applications in collaboration with AstraZeneca. Her work spans nanotechnology, drug delivery, materials science, and pharmaceutical engineering.Beyond the lab, Dr. King has built a remarkably interdisciplinary career. She trained as an officer cadet with the Royal Air Force, interned with NASA Goddard Space Flight Center on the Curiosity Rover's Sample Analysis at Mars program, studied at the International Space University, and has become a leading advocate for using space technology to benefit humanity on Earth.Dr. King is also a passionate science communicator and STEM advocate, serving as a Tech She Can Ambassador and helping inspire the next generation of women entering science and technology fields.Dr. King has been recognized as an Everywoman in Tech Innovator Award winner and one of Codex World's Top 50 Innovators - and today, she joins us to discuss one of the most fascinating frontiers in medicine: manufacturing pharmaceuticals in space.#SpacePharma #BioOrbit #KatieKing #SpaceMedicine #Microgravity #CancerResearch #Biotech #FutureOfMedicine #SpaceTech #OrbitalManufacturing #Nanomedicine #LongevityScience #ISS #DrugDiscovery #CancerTherapy #SpaceBiology #Pharmaceuticals #Innovation #DeepTech #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailWhat if the biggest public health threat to attention, sleep, relationships, and mental health isn't a virus or a disease - but the device in your pocket?Dr. Nidhi Gupta, MD ( https://reconnect.expert/Dr-Nidhi-Gupta ) is a pediatric endocrinologist, TEDx speaker, researcher, entrepreneur, and one of the leading voices exploring the intersection of technology, health, and human connection in the digital age.Dr. Gupta is the Founder of the Phreedom Foundation, a nonprofit organization built around a simple but increasingly urgent mission: helping individuals, families, schools, and workplaces reclaim their time, attention, and sense of presence in a world dominated by screens and smart devices. Through coaching, retreats, school partnerships, and corporate workshops, she has helped spark a growing movement toward intentional living and healthier relationships with technology.Long before “screen addiction,” “digital burnout,” and “attention fragmentation” became mainstream concerns, Dr. Gupta was already raising alarms about the hidden physiological and psychological costs of our always-connected culture. Her research and clinical observations have linked excessive digital engagement to anxiety, sleep disorders, burnout, obesity, diminished focus, and increasing social disconnection - especially among children and adolescents.In parallel with her digital wellness work, Dr. Gupta is also the Founder of KAP Pediatric Endocrinology ( https://www.kapendocrine.com/ ), where she practices a direct-care model focused on personalized, unhurried medicine and deeper physician-patient relationships. She previously served as Assistant Professor of Pediatrics at Vanderbilt University Medical Center and completed her pediatric endocrinology fellowship at Mayo Clinic College of Medicine and Science.Dr. Gupta is also the best-selling author of Calm the Noise ( https://www.amazon.com/Calm-Noise-Digital-Addiction-Generation-ebook/dp/B0FPBSTR55 ), a deeply personal and science-based guide to navigating modern life with greater clarity, balance, and intentionality.On this episode we explore the neuroscience and physiology of digital overuse, what screens are doing to our children and ourselves, the loneliness paradox of hyperconnectivity, the future of attention in the AI era, and how we can begin rebuilding healthier, more meaningful human lives in a world increasingly mediated by technology.#NidhiGupta #DigitalWellness #CalmTheNoise #ScreenAddiction #SmartphoneAddiction #MentalHealth #AttentionEconomy #DigitalDetox #Healthspan #BrainHealth #SleepHealth #Burnout #Parenting #ChildrenAndScreens #TechnologyAddiction #Longevity #Mindfulness #Focus #Neuroscience #Podcast #HealthPodcast #ScreenTime #Dopamine #DigitalBalance #WellnessSupport the show

Send us Fan MailEvery year, thousands of newborns suffer devastating brain injury during birth - and despite decades of research, there are still no approved drug therapies for Hypoxic Ischemic Encephalopathy (HIE). But one biotech company believes it may finally have a solution.Dr. Howard Berman, Ph.D. is Chief Executive Officer and Chairman of ReAlta Life Sciences ( https://realtalifesciences.com/ ), a clinical-stage biotechnology company developing novel therapies for severe inflammatory diseases.Dr. Berman brings a unique background spanning neuroscience, pharmacology, medical affairs, technology transfer, and biotech entrepreneurship. He earned his Ph.D. in Pharmacology and Neuroscience from Weill Cornell Medical College, where his research focused on pain and temperature processing in the human brain using functional MRI. Over the course of his career, he has held roles at Novartis, Eli Lilly and Company, and AbbVie, working across oncology, neuroscience, immunology, and business development.Dr. Berman later went on to found Coya Therapeutics, a company focused on regulatory T-cell biology and neurodegenerative disease, and has built a reputation for identifying and advancing novel therapeutic approaches at the intersection of science and translational medicine.Today, Dr. Berman is leading ReAlta at a particularly important moment for the company. ReAlta recently announced a $40 million financing round to support the continued development of its lead therapeutic candidate, pegtarazimod, for the treatment of Hypoxic Ischemic Encephalopathy, or HIE.HIE is a devastating condition caused by a lack of oxygen and blood flow to the brain during or around the time of birth. It remains one of the leading causes of neonatal mortality and long-term neurological disability worldwide, often resulting in conditions such as cerebral palsy, epilepsy, and cognitive impairment. Despite decades of research, there are currently no approved drug therapies specifically targeting the underlying inflammatory injury associated with HIE.Pegtarazimod represents a novel approach. Derived from a naturally occurring viral peptide, the therapy is designed to modulate two major upstream drivers of inflammatory damage - the complement system and neutrophil-mediated inflammation. Rather than focusing on a single downstream pathway, the strategy aims to intervene earlier in the inflammatory cascade that contributes to ongoing brain injury following hypoxic events.The company's ongoing Phase 2 STAR trial is currently evaluating pegtarazimod in newborns with moderate to severe HIE undergoing therapeutic hypothermia, which remains the current standard of care.In this conversation, we discuss:- the biology and clinical burden of HIE,- why past therapeutic approaches have struggled,- the scientific origins of pegtarazimod,- how virus-derived peptides may open new approaches to immune modulation,- and what success could ultimately mean for neonatal medicine and inflammatory disease more broadly.#NeonatalCare #HIE #HypoxicIschemicEncephalopathy #BrainInjury #NewbornHealth #Biotech #Inflammation #Neuroscience #NICU #DrugDevelopment #Pharma #HealthcareInnovation #ComplementSystem #Immunology #RareDisease #ClinicalTrials #Pediatrics #MedicalInnovation #ReAlta #HowardBerman #FutureOfMedicine #PrecisionMedicine #Neuroprotection #LifeSciences #ProgressPotentialPossibilitiesSupport the show

Send us Fan MailOn any given night, more than 750,000 people are homeless in America - but that number doesn't even begin to tell the full story.Today's conversation sits at the intersection of advocacy, lived experience, and storytelling - because ending homelessness isn't just a policy challenge, it's a human one.Our first guest, Donald Whitehead Jr., is one of the leading voices in the fight to end homelessness in America. As Executive Director of the National Coalition for the Homeless ( https://nationalhomeless.org/ ), he brings more than 25 years of frontline and leadership experience across housing, recovery, and social services. But Donald's work is also deeply personal - having experienced homelessness and addiction himself, he now helps shape national policy, elevate lived voices, and push for a more equitable system rooted in dignity and justice.Joining him is Valerio Zanoli ( https://www.valeriozanoli.com/ ), an award-winning filmmaker and social entrepreneur who believes cinema can be a force for change. His latest documentary, HOMELESS ( https://homelessdocumentary.com/ ), goes beyond statistics to humanize the experience of homelessness - exploring the stories, dreams, and resilience of people too often overlooked. The film has already been featured at global forums and praised for its emotional depth and social impact ( https://buffalo8.com/project/homeless/ ).Together, they represent two powerful lenses on the same issue: one from the front lines of advocacy and systems change, the other from behind the camera - shaping how the world sees and understands homelessness.Let's Make a Difference Project - www.letsmakeadifference.info#Homelessness #HousingCrisis #EndHomelessness #SocialImpact #DocumentaryFilm #HousingFirst #PublicPolicy #AffordableHousing #MentalHealthAwareness #EconomicInequality #LasVegas #UrbanCrisis #NonprofitLeadership #StorytellingForChange #HumanStories #SocialJustice #Inequality #HomelessInAmerica #PolicyDebate #ImpactFilmSupport the show

Send us Fan MailThere's a hidden supply chain crisis happening in fine dining right now - and it's something as simple, and as essential, as chocolate.Brandon Olsen is a world-class chef and chocolatier known for blending high-end culinary artistry with bold, modern creativity. He trained at some of the most prestigious kitchens in the world, including The French Laundry under Thomas Keller, before becoming a standout force in Toronto's culinary scene.Brandon is the founder of CXBO Chocolates and co-founder of La Banane, where his visually striking and technically precise desserts - most famously the “Ziggy Stardust Disco Egg” - earned widespread acclaim.Now, Brandon is making a pivotal shift from chocolatier to chocolate maker. As co-founder of As We Do Chocolate Company ( https://aswedochocolates.com/ ), he is stepping upstream in the value chain - taking control of the full bean-to-bar process to reimagine how chocolate is designed, produced, and delivered for professional kitchens.Michael Held is a seasoned entrepreneur and capital strategist with nearly 35 years of experience building and scaling companies across industries. He is best known as the founder of LifeSpeak Inc., a digital mental health platform he grew from inception to approximately $50 million in annual recurring revenue before taking it public at a valuation of roughly half a billion dollars.With a background spanning law, management consulting, and high-growth technology ventures - including roles at Monitor Group and Borden Ladner Gervais LLP - Michael brings deep expertise in scaling operations, capital formation, and strategic growth.At As We Do Chocolate, Michael is focused on building the infrastructure and operational backbone required to create something rare in food: a scaled, chef-driven manufacturing platform designed to serve the evolving needs of North American hospitality.#ChocolateIndustry #BeanToBar #FoodSupplyChain #ChefLife #PastryChef #FoodInnovation #HospitalityIndustry #RestaurantBusiness #FoodTech #SupplyChainCrisis #CulinaryArts #GourmetDesserts #FineDining #Entrepreneurship #StartupStory #FoodManufacturing #MadeInNorthAmerica #LuxuryFood #ChocolateLovers #KitchenSecrets #BehindTheScenesFood #DisruptingIndustry #ScalingCraft #FoodBusiness #FutureOfFoodSupport the show

Send us Fan MailWhat if you could ship a nuclear power plant like a container - and run it for years without refueling?Josef Freundorfer is the CEO of Nuclea Energy ( https://www.nuclea.energy/ ), where he is leading the development of next-generation nuclear microreactors designed to bring reliable, zero-carbon power to some of the world's most challenging environments.An engineer by training, Josef brings hands-on experience across reactor design, fuel handling, and nuclear operations - having worked at Bruce Power and Candu Energy - combined with a strategic perspective shaped by his role as founder and president of Nuclear Potential Canada, where he has been an active voice in advancing nuclear innovation and public understanding.At Nuclea, Josef is spearheading the development of the Morpheus Reactor - a lead-cooled, graphite-moderated microreactor platform aimed at powering remote communities, mining operations, defense installations, and energy-intensive infrastructure like data centers.With a growing patent portfolio in nuclear plant design and a career spanning engineering, policy advocacy, and entrepreneurship, Josef sits at the intersection of technology, regulation, and market deployment - working to redefine how nuclear energy is built, deployed, and scaled in the 21st century.#nuclearenergy #microreactors #smallmodularreactors #SMR #advancednuclear #cleanenergy #energytransition #nuclearpower #HALEU #nextgenerationenergy #energydisruption #climatetech #deepphysics #energysecurity #AIinfrastructure #datacenters #miningenergy #offgridpower #leadcooledreactor #nuclearinnovation #canadanuclear #futureenergySupport the show

Send us Fan MailWe may be building something entirely new - a kind of digital nervous system for the planet, where satellites and AI are constantly sensing and interpreting what's happening on Earth.Sean Donegan is the Founder and CEO of Satelytics ( https://www.satelytics.com/ ), a pioneer in applying artificial intelligence to high-resolution satellite imagery to monitor and protect critical infrastructure at global scale. With more than three decades of experience in enterprise software and predictive analytics, Sean has built a career at the intersection of data, automation, and real-world industrial problem solving.Long before “GeoAI” became a buzzword, Sean recognized the potential of combining remote sensing with advanced analytics to deliver continuous, actionable intelligence across vast physical assets - pipelines, power grids, and water systems that were historically difficult to monitor in real time. Under his leadership, Satelytics has helped move satellite-based monitoring from experimental pilot programs into core operational systems, enabling energy and utility companies to detect methane leaks, identify environmental risks, and prevent costly infrastructure failures before they escalate.Sean is a serial entrepreneur who has founded or led four successful software companies. Prior to Satelytics, he spent 15 years as CEO of Westbrook Technologies, where he engineered one of the more dramatic turnarounds in enterprise software - transforming a struggling firm into a profitable global leader serving customers in more than 50 countries. Earlier, he developed predictive analytics platforms for the oil and gas sector through his firm Sean Allen LLC, laying the groundwork for the industrial AI applications he is advancing today.Known for his energetic leadership style and sharp wit, Sean combines deep technical insight with a practical understanding of how large industrial operators adopt new technologies. Today, he is at the forefront of a major shift in how the world's most critical infrastructure is monitored - where satellites, AI, and falling data costs are converging to make continuous, global surveillance not just possible, but essential.#GeoAI #SatelliteTechnology #ArtificialIntelligence #MethaneDetection #OilAndGas #EnergyInnovation #ClimateTech #RemoteSensing #SpaceTech #Infrastructure #Utilities #EnvironmentalMonitoring #DataAnalytics #PredictiveAnalytics #SmartInfrastructure #WildfirePrevention #TechPodcast #FutureOfAI #IndustrialAI #EarthObservationSupport the show

Send us Fan MailDoctors in North America are now prescribing something you can't buy at a pharmacy… and it's backed by a growing body of science. Jennie McCaffrey is the Vice President of Health & Education at the BC Parks Foundation ( https://bcparksfoundation.ca/ ), where she leads initiatives designed to connect people to nearby nature for the benefit of both human health and the planet.With a career spanning environmental education, behavior change, and large-scale community engagement, Jennie has worked across nonprofits, government, and industry to inspire action on biodiversity, climate, and public health. Her work has helped build movements around ambitious conservation goals like 25x25 and 30x30, while also translating those global targets into everyday human behaviors - getting people outside, active, and reconnected with nature.Before stepping into her current role, Jennie led education and engagement efforts at the Invasive Species Council of BC, where she scaled programs dramatically during a period of rapid organizational growth. She has also spent over a decade delivering hands-on environmental education through the Habitat Conservation Trust Foundation and its WildBC program, empowering communities to better understand and protect the natural world.Jennie holds a Master's in Environmental Education and a Bachelor's in Conservation Biology from University of British Columbia, and she brings both scientific grounding and deep community experience to her mission: making nature a daily, accessible part of people's lives - and a cornerstone of healthier societies.#NatureAsMedicine #HealthyByNature #ParkPrescriptions #PaRx #PreventiveHealth #PublicHealthInnovation #MentalHealth #Longevity #BehaviorChange #EnvironmentalHealth #Biodiversity #ClimateAndHealth #OutdoorWellness #NatureTherapy #HealthcareInnovation #FutureOfHealth #PopulationHealth #WellnessStrategy #UrbanNature #HealthOptimization #BiohackingNature #Sustainability #BCParks #HumanPerformance #NatureConnectionSupport the show

Send us Fan MailToday on Progress, Potential And Possibilities, we explore a different kind of breakthrough in cognitive health - not a drug, not a device, but a simple daily practice that's quietly transforming lives.Our guest is Rob Liebreich, President and CEO of Goodwin Living ( https://goodwinliving.org/ ), an organization serving thousands of older adults across the Washington, D.C. region. Rob has spent more than two decades at the forefront of senior living and aging services - leading large-scale communities, building platforms to improve how families navigate care decisions, and working to fundamentally shift the narrative around aging from one of decline to one of purpose and possibility.But this story isn't just professional - it's deeply personal.When Rob's mother began experiencing cognitive decline, he refused to accept that deterioration was inevitable. Drawing on both his industry experience and a willingness to experiment, he developed a simple daily regimen - reading aloud, handwriting, and doing math - that helped her regain engagement, confidence, and independence.What began as a personal intervention evolved into StrongerMemory ( https://strongermemory.org/ ), a free, research-backed program now used by more than 60,000 seniors nationwide. Supported by emerging research from George Mason University, StrongerMemory is challenging conventional assumptions about what's possible in cognitive aging - and who gets access to meaningful care.At a time when memory care can cost thousands of dollars per month and pharmaceutical solutions remain limited, Rob's work raises a powerful question:What if one of the most effective tools for brain health isn't something you buy - but something you do, every day?#CognitiveDecline #Alzheimers #DementiaCare #BrainHealth #Neuroplasticity #AgingWell #Longevity #MemoryCare #SeniorLiving #HealthcareInnovation #PreventativeHealth #NonPharmacological #BrainTraining #MentalFitness #Caregiving #AgingPopulation #DigitalHealth #Healthspan #PodcastClips #FutureOfHealthcare #Wellness #CognitiveHealth #BrainExercises #StrongerMemory #Neuroscience #LongevityScience #HealthyAging #PublicHealthSupport the show

Send us Fan MailIn times of crisis, innovation doesn't slow down - it accelerates.Over the past several years, Ukraine has become globally recognized for its rapid advances in defense technology - particularly in drones and distributed manufacturing. But alongside that transformation, another revolution has been quietly taking shape: the future of medicine, built under extreme conditions.Today, we're exploring that frontier through the work of biodrook (https://biodrook.com/en) - a company developing 3D-printed, biodegradable bone implants designed to help the body regenerate itself.And joining me are three of the leaders building that vision.Denys Gurak is the Founder of biodrook and a longtime innovator at the intersection of technology, policy, and defense. Through his work at MITS Capital, he's been deeply involved in scaling Ukraine's defense-tech ecosystem and connecting it to global supply chains - bringing a systems-level perspective on how innovation happens under pressure.Kateryna Osetrova is Executive Director for Ukraine at biodrook, with a background spanning stem cells, exosome-based therapies, and regenerative medicine. She brings a deep understanding of how these technologies move from concept to clinical reality - and what it takes to deliver them to patients.Michael Pluzhnyk is biodrook's Chief Technology Officer, and is leading the engineering and production of these next-generation implants - translating cutting-edge materials science and 3D printing into real-world medical devices now being deployed in Ukraine.Together, they represent something rare: the convergence of vision, biology, and engineering - applied not in ideal conditions, but in one of the most challenging environments imaginable.So this is a conversation about more than just medical technology.It's about rebuilding the human body.It's about building systems that can operate under extreme stress.And ultimately, it's about what the future of medicine looks like when innovation is no longer optional - but necessary.biodrook Video - https://youtu.be/sK2Y_-A17MI?si=fliuc8oSgaqWxGIE#biotech #regenerativemedicine #3dprinting #bioprinting #medtech #futureofmedicine #healthcareinnovation #orthopedics #tissueengineering #biodegradable #startups #ukraine #innovation #science #technology #medicalbreakthrough #healthtech #longevity #deeptech #engineering #biomaterials #venturecapital #defensetech #futuretechSupport the show

Send us Fan MailToday's conversation sits at the intersection of one of the most ambitious - and most challenging - frontiers in modern medicine: regenerative cell therapy.For decades, the vision has been incredibly compelling - replace damaged or dying cells with healthy ones, and you could potentially restore function in diseases like macular degeneration, spinal cord injury, hearing loss, and even Type 1 diabetes. But while the science has advanced, the field has consistently run into a different kind of barrier: how do you actually manufacture living cells as consistent, scalable, affordable therapies?That's not just a biology problem - it's an engineering, manufacturing, and business problem.And it's one that today's guest has spent his entire career navigating.Brian Culley brings more than three decades of experience across the life sciences industry, spanning drug development, business development, and executive leadership. From early work in neuropharmacology at Neurocrine Biosciences, to technology transfer at University of California, San Diego, to building and leading public biotech companies like Mast Therapeutics, he's seen the industry from nearly every angle - science, capital markets, partnerships, and operations.Today, as CEO of Lineage Cell Therapeutics ( https://lineagecell.com/ ), Brian is applying that full spectrum of experience to one of the hardest problems in medicine: how to turn the promise of regenerative cell therapy into something that can actually reach patients at scale.Under his leadership, Lineage has taken a manufacturing-first approach - building an integrated platform designed to deliver high-quality, ‘off-the-shelf' cell therapies - and in the process has secured major partnerships with companies like Genentech and William Demant.Today, we're going to explore not just the promise of cell therapy - but what it really takes to make it real.#CellTherapy #RegenerativeMedicine #Biotech #StemCells #Longevity #FutureOfMedicine #HealthcareInnovation #Biotechnology #GeneTherapy #MedicalBreakthrough #DrugDevelopment #PrecisionMedicine #LifeSciences #Pharma #BiotechCEO #StartupBiotech #Innovation #SciencePodcast #Healthcare #AgingResearch #VisionRestoration #HearingLoss #SpinalCordInjury #Type1Diabetes #Genentech #LineageCellTherapeuticsSupport the show

Send us Fan MailImagine a device that can sense disease in real time… and treat it instantly. That's the promise of Bioelectronics.Dr. Robert Spoelgen, Ph.D. is Vice President and Head of Bioelectronics at Merck KGaA Darmstadt Germany ( https://www.emdgroup.com/en/the-future-transformation/healing-power-electronics.html ), where he leads one of the company's most forward-looking initiatives at the intersection of neuroscience, medical devices, and digital health. In this role, he founded and now drives Merck KGaA Darmstadt Germany's bioelectronics strategy, focused on developing implantable neurostimulation technologies - particularly selective peripheral nerve stimulation platforms - to treat chronic diseases and enable real-time patient monitoring.Dr. Spoelgen's work reflects a broader shift within pharma toward “beyond the pill” modalities, combining device-based therapies with data-driven insights. His team collaborates with medtech partners to develop precision neuromodulation approaches, including vagus nerve stimulation platforms aimed at conditions ranging from hypertension to inflammatory disease.Before launching bioelectronics at Merck KGaA Darmstadt Germany, Dr. Spoelgen led Technology Foresight & Scouting, where he helped identify and incubate new innovation domains including AI-driven drug discovery, liquid biopsy, neuromorphic systems, and synthetic biology. He was also a co-founder of Merck KGaA Darmstadt Germany's internal Business Builder unit, designed to create new ventures beyond the company's traditional portfolio.Earlier in his career, Dr. Spoelgen held executive and R&D leadership roles across biotech and med-tech, including serving as CEO of Anteis S.A. and leading medical device R&D at Merz Pharmaceuticals. His scientific foundation is in molecular neuroscience: he completed his PhD at the Max Delbrück Center and a postdoctoral fellowship at Harvard Medical School under Brad Hyman, focusing on Alzheimer's disease and neurodegeneration.Dr. Spoelgen's early research - spanning amyloid biology, synaptic signaling, and neurogenesis - resulted in publications in leading journals such as Neuron, PNAS, and Journal of Neuroscience. This deep neuroscience background now informs his efforts to translate neural circuit insights into programmable therapeutic systems.#Bioelectronics #VagusNerve #Neurostimulation #FutureOfMedicine #DigitalHealth #PrecisionMedicine #Neuroscience #MedTech #HealthcareInnovation #Pharma #DrugDiscovery #Neurotechnology #ChronicDisease #Inflammation #AIinHealthcare #ClosedLoopSystems #Electroceuticals #MedicalDevices #Biotech #MerckKGaASupport the show

Send us Fan MailToday's conversation is part of a new series we're launching — ‘Past Forward: Lessons for the Next Century.' In this series, we examine pivotal moments, systems, and individuals from the past - not to relive them, but to better understand how they continue to shape the world we are building.  Because many of the defining forces of our time - globalized networks, technological escalation, public health crises, and the evolution of law enforcement - did not emerge in isolation. They evolved from earlier systems, earlier decisions, and earlier actors operating under very different constraints.Today's episode is titled: ‘The Architecture of a Drug Empire — and the Systems It Forced the World to Build.'Carlos Lehder is one of the central figures in the rise of the Medellín Cartel, and someone who played a key role in developing the logistics and infrastructure that helped transform the global cocaine trade. After decades of imprisonment, he has recently published a firsthand account of that era in his book, Life and Death of the Medellín Cartel ( https://www.amazon.com/DEATH-MEDELL%C3%8DN-CARTEL-CARLOS-LEHDER/dp/B0FDL8D66M/ ) a narrative that traces his journey from early criminal activity to the creation and evolution of one of the most consequential criminal networks in modern history.This conversation is not about glamorizing crime or revisiting mythology. It is about understanding systems - how they scale, how they collide with institutions, and how their consequences ripple across decades.Across this discussion, we explore themes that connect directly to many conversations we've had on this show - from the evolution of global law enforcement and emerging technologies, to drug policy, harm reduction, incarceration, and even healthcare behind bars.And ultimately, the goal is simple: to extract lessons. Lessons about innovation and unintended consequences. Lessons about policy and adaptation. And lessons that may help us better understand - and perhaps better navigate - the systems we are building for the future.#PastForward #ProgressPotentialPossibilities #CarlosLehder #MedellinCartel #PabloEscobar #DrugPolicy #WarOnDrugs #TrueCrime #Geopolitics #CriminalJustice #LawEnforcement #DEA #HistoryMatters #SystemsThinking #GlobalSecurity #OrganizedCrime #Innovation #PublicHealth #HarmReduction #FutureOfPolicing #AIandCrime #DrugEpidemic #ColdWarHistory #TransnationalCrime #PodcastSupport the show

Send us Fan MailWhat if a simple blood test could detect Alzheimer's years—maybe even decades—before symptoms ever appear?Mike Banville is the Chief Executive Officer of ALZpath ( https://alzpath.bio/ ), a company at the forefront of transforming how Alzheimer's disease is detected and monitored through cutting-edge blood-based diagnostics.Mike is a seasoned global executive with a track record of scaling businesses, driving operational transformation, and executing strategic growth through both organic expansion and acquisitions. Prior to ALZpath, he served as CEO of SSB - doubling revenue and shifting the business to a predominantly recurring revenue model.Earlier in his career, Mike spent over two decades at IHS Markit, where he held multiple senior leadership roles across strategy, sales, marketing, and global operations. There, he helped scale the Telecommunications, Media, and Technology division through acquisitions and product integration, while also leading global offshoring strategy and climate-focused market development initiatives.Mike has also led and turned around companies in digital health and athlete development, bringing a consistent focus on data, analytics, and scalable platforms.Now at ALZpath, Mike is applying that same operational and strategic expertise to one of the most urgent challenges in medicine - enabling earlier, more accessible detection of Alzheimer's disease through innovative biomarker technologies, like pTau217, helping accelerate research, improve clinical care, and ultimately impact millions of patients worldwide.#Alzheimers #AlzheimersDisease #Dementia #BrainHealth #Longevity #Biotech #HealthcareInnovation #Diagnostics #BloodTest #EarlyDetection #Neuroscience #Neurodegeneration #PrecisionMedicine #FutureOfMedicine #MedTech #Biomarkers #TauProtein #pTau217 #StartupCEO #BiotechCEO #HealthcarePodcast #MedicalBreakthrough #AgingResearch #CognitiveHealth #LifeSciencesSupport the show

Send us Fan MailThere's a revolution happening in pet health right now - where a simple stool sample can reveal disease risk, immune health, and even how long your dog might live.Dr. Bushra Schuitemaker, Ph.D. is a microbiologist, zoologist, and science leader working at the cutting edge of microbiome research, animal health, and nutrition. Dr. Schuitemaker serves as Head of Science and Research at BIOME9 ( https://biome9.com/ ), a leading platform for canine gut microbiome analysis, and Head of Microbiology at Pooch & Mutt ( https://www.poochandmutt.co.uk/ ), where she helps translate microbiome science into real-world products and interventions for pet health.Dr. Schuitemaker's work sits at the intersection of microbial ecology, bioinformatics, and machine learning, where she develops tools to decode the gut microbiome and turn complex data into actionable insights for veterinarians, pet owners, and the pet food industry. Her expertise spans metagenomics, metabolomics, and multi-omics integration, with a focus on identifying biomarkers that can drive precision health approaches in animals.Dr. Schuitemaker completed her Ph.D. in Zoology at the University of East Anglia, where she pioneered microbiome-based biomarkers of poultry gut health, and has also contributed to human health research, including microbiome and metabolomics studies in childhood obesity.A passionate advocate for “One Medicine” - the idea that human and animal health are deeply interconnected - Dr. Schuitemaker is also an active science communicator, collaborating across academia, industry, and policy to make microbiome science more impactful, inclusive, and accessible.#Microbiome #DogHealth #GutHealth #CanineMicrobiome #PetHealth #DogLongevity #VeterinaryScience #OneMedicine #OneHealth #PrecisionNutrition #Bioinformatics #MachineLearning #AnimalHealth #PetCare #DogsOfYouTube #DogWellness #HealthScience #FutureOfMedicine #LongevityScience #Metagenomics #Biome9 #PoochAndMutt #SciencePodcast #Biotech #AgingResearchSupport the show

Send us Fan MailWhat if most dogs aren't dying of old age - but from losing their ability to move?Dr. Laurie McCauley, DVM, DACVSMR, CCRT, CVA, CVC is a pioneer in veterinary rehabilitation and one of the most influential figures in canine sports medicine. With over two decades at the forefront of the field, she founded the first dedicated veterinary rehabilitation clinic in the United States and designed the world's first underwater treadmill specifically for dogs - innovations that helped transform how veterinarians approach mobility, recovery, and performance in animals.A board-certified specialist in Canine Sports Medicine and Rehabilitation, Dr. McCauley has trained thousands of veterinarians, physical therapists, and rehabilitation professionals around the world, and her work has played a central role in shaping modern standards of care.Dr. McCauley is the founder and instructional director of Optimum Pet Vitality ( https://optimumpetvitality.com/ ), an education platform focused on delivering evidence-based, practical training to veterinary professionals and pet owners alike, covering areas such as therapeutic exercise, laser therapy, and fascia-based treatments.In addition, Dr. McCauley is the owner of Red Tail Rehab, where she provides personalized, in-home rehabilitation care, helping animals improve mobility, reduce pain, and enhance quality of life.Dr. McCauley's career has been defined by a singular mission: to help animals move better, feel better, and ultimately live longer, healthier lives.#DogLongevity #PetHealth #CanineRehab #DogAging #VeterinaryMedicine #PetWellness #HealthyPets #DogHealth #LongevityScience #AnimalHealth #PetCareTips #SeniorDogs #CanineHealth #MobilityMatters #PetLongevity #VeterinaryRehabilitation #DogFitness #AgingResearch #BiohackingPets #HealthspanSupport the show

Send us Fan MailWhat if paralysis wasn't permanent—but just a biological system we haven't figured out how to reboot?Dr. Lior Shaltiel, Ph.D. is Chief Executive Officer of NurExone Biologic ( https://nurexone.com/ ), a biotech company pioneering a novel exosome-based platform aimed at repairing the central nervous system.Dr. Shaltiel brings a rare combination of deep scientific training and cross-border biotech leadership. He earned his Ph.D. in molecular pharmacology from Ludwig Maximilian University of Munich, where his research focused on ion channels and retinal biology - early work that connects directly to today's frontier in neuroregeneration.Before stepping into the CEO role, Dr. Shaltiel led R&D programs in advanced drug delivery systems, including liposome-based therapeutics, and worked in global biotech investment and partnerships. He's also the founder of the BioMed MBA program at Hebrew University of Jerusalem, helping train the next generation of biotech leaders.At NurExone, Dr. Shaltiel is advancing the company's ExoTherapy platform - leveraging extracellular vesicles to deliver targeted genetic payloads. Their lead program, ExoPTEN, is an intranasal exosome therapy designed to silence the PTEN gene and promote neuronal regeneration after spinal cord injury - an area where, to date, there are no approved treatments that restore lost function.#biotech #neuroscience #spinalcordinjury #regenerativemedicine #exosomes #stemcells #futureofmedicine #geneediting #biotechinnovation #medicalbreakthrough #neuroregeneration #sciencepodcast #healthtech #longevity #drugdiscovery #PTEN #RNAi #nextgenmedicine #biophysics #medtechSupport the show

Send us Fan MailWhat if the biggest barrier in healthcare today isn't science - but stigma?Eric Foster is Chief Commercial Officer at Ardelyx ( https://ardelyx.com/ ), a biopharmaceutical company where he leads global commercialization strategy for innovative therapies addressing high-burden gastrointestinal and cardiorenal diseases. A seasoned biotech executive with over two decades of experience, Eric has built and scaled high-performing commercial organizations across some of the industry's most complex and competitive markets.Prior to Ardelyx, Eric held senior leadership roles at Amgen and Horizon Therapeutics, where he led rare disease and specialty business units, overseeing product launches, market access, and global growth strategy. Earlier in his career, he spent over a decade at GSK and began in commercial roles at Johnson & Johnson.Eric is known for his expertise in rare disease commercialization, payer strategy, and building first-in-class market entry plans, with a strong focus on connecting patients to therapies and reducing barriers to care. He holds an MBA in Healthcare from Auburn University and a BA in Economics from the University of Georgia.#IBSC #GutHealth #WomensHealth #HealthcareInnovation #Biotech #PharmaMarketing #LPGA #WomensSports #DigitalHealth #PatientAwareness #ChronicIllness #HealthEducation #MedicalInnovation #HealthcareMarketing #BehaviorChange #HealthStigma #ChronicDisease #Biopharma #HealthPodcast #FutureOfHealthcareSupport the show

Send us Fan MailWhat if we could restore vision, communicate directly with the brain, and even extend human life—not with machines alone, but with living, engineered biology?Dr. Alan Mardinly, Ph.D. is the Chief Scientific Officer and Co-Founder of Science Corp. ( https://science.xyz/ ), a neurotechnology company developing next-generation brain interfaces and biohybrid neural implants aimed at restoring human function.Dr. Mardinly leads the company's biohybrid program, focused on combining genetically engineered cells with advanced optical hardware to create optogenetic therapies for vision restoration and new types of brain-machine interfaces.Dr. Mardinly has spent more than 15 years working at the intersection of neuroscience, genetics, and neural engineering. Dr. Mardinly earned his PhD in Neurobiology from Harvard University, where his research explored how experience and activity-dependent gene programs shape synaptic plasticity in inhibitory neurons—work that helped illuminate how neural circuits maintain stability while adapting to learning and sensory experience.Following Harvard, Dr. Mardinly conducted postdoctoral research at UC Berkeley, where he helped pioneer holographic optogenetics, a technology capable of stimulating specific neurons with extraordinary spatial and temporal precision.Dr. Mardinly later joined Neuralink, where he served as Director of Biology, leading teams focused on advancing brain-machine interface technologies. In 2021, Dr. Mardinly co-founded Science Corp., where he now works to translate cutting-edge neuroscience into therapeutic systems designed to restore vision and build the next generation of neural interfaces.#Neurotechnology  #BrainComputerInterface #Optogenetics #VisionRestoration #Biohybrid #ScienceCorp #Neuralink #FutureOfMedicine #BrainImplants #ArtificialVision #Neuroscience #Biotech #Longevity #LifeSupport #SyntheticBiology #HumanAugmentation #NextGenMedicine #DeepTech #Innovation #FutureOfHealthcareSupport the show

Send us Fan MailThere are over 9,000 rare diseases affecting 300 million people—and yet 90% of them have no approved treatment. Why?Craig Martin is the Founder and CEO of Orphan Therapeutics Accelerator ( https://www.orphantxl.com/ ), a pioneering nonprofit launched in 2024 to advance shelved therapies for ultra-rare diseases—bringing overlooked science back to life and guiding it through approval and into patients' hands through innovative development and commercialization pathways.With more than two decades at the intersection of biotech, digital health, and healthcare strategy, Craig has built a career around unlocking value in overlooked opportunities and tackling some of medicine's toughest challenges. He previously founded Rithm Health, where he has advised emerging biotech and health technology companies on strategy, growth, and stakeholder engagement.Craig also served as CEO of Global Genes, one of the world's leading rare disease patient advocacy organizations, where he reversed declining revenues, launched major new initiatives, and led a successful merger with RARE-X—expanding the organization's impact across the rare disease ecosystem.Earlier in his career, Craig spent over a decade leading Ogilvy | Feinstein Kean Healthcare, and held leadership roles at Ogilvy Consulting and Ruder Finn, advising global pharma, biotech, and health innovators.A graduate of Duke University, Craig brings a unique blend of strategic insight, policy awareness, and deep commitment to patients—focused on transforming how therapies for ultra-rare diseases are developed, financed, and delivered.#RareDisease #UltraRareDisease #Biotech #HealthcareInnovation #DrugDevelopment #GeneTherapy #OrphanDrugs #Pharma #MedicalInnovation #FutureOfMedicine #HealthTech #LifeSciences #BiotechInnovation #DrugDiscovery #PatientAccess #Healthcare #Medicine #Science #Innovation #NonprofitBiotech #RareDiseaseAwareness #GlobalHealthSupport the show

Send us Fan MailInside a fusion reactor, you're not just creating a star—you're building a machine that has to survive one. Temperatures hotter than the sun, relentless neutron bombardment… and materials that slowly destroy themselves from the inside out.Daniel Clark is a nuclear engineer and fusion energy expert working at the forefront of turning fusion from a scientific pursuit into a practical energy solution.Daniel is currently Director of Nuclear and Fuel Cycle Engineering at Type One Energy Group ( https://typeoneenergy.com/ ), where he leads critical efforts in breeder blanket and first wall design, as well as the tritium fuel cycle - core systems that will ultimately determine whether fusion reactors can operate sustainably at scale.Prior to joining the private sector, Daniel spent nearly eight years at the U.S. Department of Energy Office of Science, where he managed the Fusion Materials Research Portfolio. During that time, he helped launch major national initiatives, including the Material Plasma Exposure eXperiment at Oak Ridge National Laboratory, the INFUSE public-private partnership program, and the Fusion Prototypic Neutron Source.With degrees in nuclear engineering from Texas A&M University and University of Tennessee, Knoxville, Daniel brings a rare combination of deep technical expertise, federal policy insight, and commercialization experience—making him one of the key voices shaping the future of fusion energy.#FusionEnergy #NuclearFusion #CleanEnergy #FutureOfEnergy #EnergyInnovation #DeepTech #ClimateTech #Physics #NuclearEngineering #MaterialsScience #EnergyTransition #Tritium #SciencePodcast #TechPodcast #HardTech #Engineering #Innovation #FusionPower #StartupEnergy #BigScience #NextGenEnergy #AdvancedMaterials #EnergyFuture #BreakthroughScience #ClimateSolutionsSupport the show

Send us Fan MailWhat if the reason we haven't explored deep space isn't because we can't… but because our engines are fundamentally too slow?Richard Dinan is Founder and CEO of Pulsar Fusion ( https://pulsarfusion.com/ ) and one of the few entrepreneurs in the world not trying to bring fusion power to Earth… but to space.While most fusion startups are focused on powering cities, Richard is building engines designed to power spacecraft—fusion propulsion systems that could dramatically cut travel times to Mars, unlock missions to Saturn's moon Titan, and fundamentally reshape how we explore the solar system.Pulsar's flagship efforts—including its Dual Direct Fusion Drive and the Sunbird program—aim to combine high-thrust propulsion with onboard power generation, a combination that could enable entirely new classes of deep-space missions. The company is now working with the United Kingdom Atomic Energy Authority on advanced neutron shielding and activation modeling—critical challenges for making fusion viable and safe in space.Backed by the UK Space Agency and collaborating with the European Space Agency, Pulsar is positioning itself at the center of a new space race—one where the bottleneck isn't getting off Earth… but moving once you're already out there.On this episode we talk about why space might be the first place fusion actually works, what it takes to build engines that can survive neutron bombardment, and whether radically faster travel could open up the outer solar system within our lifetime.#fusionenergy #spacetechnology #spaceexploration #marsmission #deepspace #futureofspace #nuclearfusion #fusionpropulsion #spacex #nasa #spaceinnovation #aerospace #futuretech #pulsarfusion #richarddinan #sciencepodcast #techpodcast #engineering #physics #spacefuture #interplanetary #spaceindustry #nextgentech #hardtech #innovation #elonmusk #spaceeconomy #ukspace #europespace #austintechSupport the show

Send us Fan MailImagine treating back pain not with surgery, not with opioids—but by using your own stem cells to repair the damage at its source.Lance Alstodt is President, CEO, and Chairman of BioRestorative Therapies, Inc. ( https://biorestorative.com/ ), a publicly traded regenerative medicine company focused on developing stem cell-based therapies to treat highly prevalent conditions, including chronic lower back pain and metabolic disorders.With more than 25 years of experience across healthcare investment banking, medical technology, and company building, Lance brings a unique perspective at the intersection of science and capital markets. Prior to joining BioRestorative, he was the founder and CEO of MedVest Consulting, advising healthcare companies on growth strategy, M&A, and capital formation.Earlier in his career, Lance held senior leadership roles at firms including Leerink Partners, Oppenheimer & Co., Bank of America Merrill Lynch, and JPMorgan Chase & Co., where he specialized in healthcare and medical technology transactions.At BioRestorative, Lance is leading the development of innovative cell therapies such as BRTX-100, an autologous mesenchymal stem cell therapy currently in Phase 2 trials for chronic lumbar disc disease, aiming to offer a non-opioid, non-surgical solution to one of the most widespread causes of disability worldwide.#StemCells #RegenerativeMedicine #BackPainRelief #Biotech #HealthcareInnovation #MedicalBreakthrough #ChronicPain #BioTech #FutureOfMedicine #StemCellTherapy #DegenerativeDiscDisease #PainManagement #HealthTech #BiotechStocks #Longevity #MedicalInnovation #CellTherapy #NonSurgicalTreatment #OpioidCrisis #SciencePodcast #HealthcareRevolutionSupport the show

Send us Fan MailWhat if we could build a fusion reactor that runs continuously—without the instability issues that have plagued the field for years?Brian Berzin is the Co-Founder and CEO of Thea Energy ( https://thea.energy/ ), a next-generation fusion company focused on advancing stellarator technology—one of the most promising but historically underexplored approaches to magnetic confinement fusion.Brian brings a unique combination of deep technical and financial expertise, with a background spanning electrical engineering, venture capital, private equity, and investment banking. Prior to founding Thea Energy, Brian served as Vice President of Strategy at General Fusion, where he helped shape commercialization strategy and led engagement with global capital markets during a pivotal period for privately funded fusion.At Thea Energy, Brian is leading efforts to “end the sun's monopoly on fusion energy” by leveraging breakthroughs in high-temperature superconducting materials and advanced computational design to build more stable and scalable fusion systems. In 2023, the company was selected as one of a small group of awardees in the U.S. Department of Energy's milestone-based fusion development program.Brian holds dual degrees in Electrical Engineering and Finance from Lehigh University, reflecting the interdisciplinary mindset he now applies to one of the hardest engineering challenges in the world: making fusion power a commercial reality.#fusionenergy #fusion #cleanenergy #nuclearfusion #stellarator #tokamak #science #energy #futureofenergy #deeptech #climatechange #renewableenergy #hightech #engineering #superconductors #HTS #fusionpower #energytransition #cleantech #futuretech #startup #innovation #sciencepodcast #energyindependence #decarbonization #physics #bigideasSupport the show

Send us Fan MailWe're living through a golden age of rare disease breakthroughs—but for many patients, the hardest part begins after the drug is approved.Today we're joined by two leaders from the multinational biopharmaceutical company UCB ( https://www.ucb.com/ ) who are helping reshape how the rare disease community thinks about what happens after a therapy is approved—because for many families, approval is just the beginning of the journey.Dr. Kim Moran, Ph.D. is Senior Vice President and Head of U.S. Rare Diseases at UCB ( https://www.ucb-usa.com/UCB-in-the-U-S/U-S-Leadership-Team/Kim-Moran ). Dr. Moran leads the company's U.S. rare disease portfolio strategy and commercial organization, integrating clinical, regulatory, operational, and digital capabilities to bring therapies to patients with devastating and often ultra-rare conditions. Trained as a neuroscientist with a PhD from NYU and an Executive MBA from INSEAD, she has spent nearly two decades at UCB translating patient insights into real-world solutions—from epilepsy portfolio strategy to leading the recent FDA approvals and launches of two major rare disease assets. Dr. Moran is widely recognized for her leadership in the industry, including honors from the Healthcare Businesswomen's Association and Medical Marketing + Media, and she remains deeply focused on ensuring scientific breakthroughs actually translate into meaningful impact for patients and families.Brad Chapman is Head of U.S. Epilepsy and Rare Syndromes at UCB ( https://www.ucb-usa.com/UCB-in-the-U-S/U-S-Leadership-Team/Brad-Chapman ). Mr. Chapman oversees one of the deepest portfolios of anti-seizure therapies in the industry, including BRIVIACT, NAYZILAM, and FINTEPLA, while leading nationwide teams focused on connecting patients with both treatment and support systems. Over more than 15 years with UCB, Mr. Chapman has helped pioneer new go-to-market models in neurology that move decision-making closer to patients and providers, strengthen partnerships with the epilepsy community, and rethink how pharmaceutical organizations deliver value “beyond the pill.”Together, Dr. Moran and Mr. Chapman sit at the intersection of scientific innovation, patient access, and community infrastructure, and they're helping answer a critical question in rare disease: How do we make sure life-changing therapies actually reach—and work for—the patients who need them most?Important Episode Link - Caring for Adults with Rare Epilepsy -https://www.ucb-usa.com/sites/default/files/2024-06/UCBCAREBinder.pdf#RareDisease #UltraRareDisease #Epilepsy #CDKL5 #DravetSyndrome #RareEpilepsy #Biotech #Pharma #DrugDevelopment #PrecisionMedicine #Geroscience #HealthcareInnovation #PatientAccess #CaregiverSupport #MedicalInnovation #Neuroscience #MitochondrialDisease #TK2Deficiency #ClinicalTrials #LifeSciences #Biopharma #HealthPolicy #FutureOfMedicine #PatientCare #InnovationSupport the show

Send us Fan MailWhether it's a battlefield, a construction site, or a farm, the challenge is the same: how do you turn massive amounts of visual data into fast, accurate decisions? Increasingly, the answer is autonomous systems. transforming how we see the world—turning raw imagery into decisions at unprecedented speed.Bill Irby is CEO and Board Member of EagleNXT ( https://eaglenxt.com/ ), a leading provider of full-stack drone, sensor, and software solutions serving both commercial and government customers worldwide.Bill brings more than 25 years of leadership experience across the unmanned systems and defense technology landscape, spanning ISR (Intelligence, Surveillance, and Reconnaissance) platforms, communications systems, and advanced autonomy. Prior to EagleNXT, Bill held senior executive roles across some of the most important defense companies in the world, including serving as President of Reconnaissance Mission Systems at L3Harris Technologies, where he led a $1.5 billion portfolio supporting some of the U.S. military's most critical airborne intelligence platforms.Bill also served as Senior Vice President and General Manager of Unmanned Systems at Textron Systems, overseeing globally deployed UAV and unmanned maritime systems, and held multiple leadership roles at Northrop Grumman, focusing on C4ISR (Command, Control, Communications, Computers, Intelligence, Surveillance, and Reconnaissance) and tactical communications.Earlier in his career, Bill served as a Combat Engineer in the United States Marine Corps, leading missions across the globe.In addition to his operational leadership, Bill has played a key role in shaping the unmanned systems ecosystem serving as Chairman of the Board of AUVSI ( Association for Uncrewed Vehicle Systems International - https://www.auvsi.org/ ), advocating for the safe integration and advancement of autonomous technologies.Bill is a graduate of the United States Naval Academy, holds a master's degree from Johns Hopkins University, and completed executive education at Harvard Business School.#DefenseTech #DroneWarfare #AutonomousSystems #MilitaryDrones #ISR #ArtificialIntelligence #FutureOfWar #UncrewedSystems #Aerospace #NationalSecurity #Robotics #AI #MilitaryTechnology #Innovation #TechPodcast #EmergingTech #BattlefieldTechnology #Surveillance #Geopolitics #StartupDefenseSupport the show